Clinical Trials in Salt Lake City

Showing 6461-6480 of 16,694 trials

A Brief Mind-Body Bridging Intervention for Suicidal Ideation

NCT03677882

The aim of this study is to determine whether a Brief Mind-Body Bridging Intervention for Suicidal Ideation (MBB-SI) will result in short or longer-term reduction of psychological factors associated with suicidal ideation (SI) and/or suicide-related behaviors (SRB's) compared to Treatment as Usual (TAU).

Suicidal IdeationMind Body Bridging

VA Salt Lake City Health Care System13 participantsStarted Dec 2018

Salt Lake City, Utah, United States

COMPLETEDPhase 1< 1 mile

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

NCT03639194

This is a multicenter, open-label, Phase 1 study of ABBV-011 given as a single agent and in combination with budigalimab (ABBV-181) in participants with relapsed or refractory small cell lung cancer (SCLC). The study consists of 4 parts: Part A is a single-agent ABBV-011 dose regimen finding cohort; followed by Part B, a single-agent ABBV-011 dose expansion cohort; and then Part C, an ABBV-011 and budigalimab (ABBV-181) combination escalation and expansion cohort; Part D, single-agent ABBV-011 dose-evaluating cohort for Japan.

Small Cell Lung Cancer

AbbVie132 participantsStarted Oct 2018

Birmingham, Alabama, United States • Springdale, Arkansas, United States • Sacramento, California, United States +29 more locations

A Brief Mind-Body Bridging Intervention for Suicidal Ideation

A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

Find Trials by Condition in Salt Lake City

PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

Pleconaril Enteroviral Sepsis Syndrome

The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Study of Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Actuate 1901: 9-ING-41 in Myelofibrosis

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)

Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA